期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 477, 期 1-2, 页码 485-494出版社
ELSEVIER
DOI: 10.1016/j.ijpharm.2014.10.048
关键词
Sodium colistimethate; Lipid nanoparticles; NLC; Pseudomonas aeruginosa; Cystic fibrosis; Nanomedicine
资金
- Ministry of Economy and Competitiveness [IPT-2011-1402-900000]
- University of the Basque Country for the ZabaldUz
- University of the Basque Country UPV/EHU, of University of Barcelona (UB) as to the CSIC [UFI11/32]
- FISIB
Lung impairment is the most life-threatening factor for cystic fibrosis patients. Indeed, Pseudomonas aeruginosa is the main pathogen in the pulmonary infection of these patients. In this work, we developed sodium colistimethate loaded lipid nanoparticles, namely, solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), as a strategy to enhance the antimicrobial therapy against P. aeruginosa in cystic fibrosis patients. The nanoparticles obtained displayed a 200-400 nm size, high drug entrapment (79-94%) and a sustained drug release profile. Moreover, both SLN and NLC presented antimicrobial activity against clinically isolated P. aeruginosa. The integrity of the nanoparticles was not affected by nebulization through a mesh vibrating nebulizer. Moreover, lipid nanoparticles appeared to be less toxic than free sodium colistimethate in cell culture. Finally, an in vivo distribution experiment showed that nanoparticles spread homogenously through the lung and there was no migration of lipid nanoparticles to other organs, such as liver, spleen or kidneys. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据